echinacea
Commercial- Indications
- immune support
Company intelligence / Profile preview
GAIA
Hamburg, Hamburg, Germanygaiagoodhealth.com ↗
- Ownership
- Private
- Employees
- ~250
- Development stage
- Commercial
01
Overview
Over 25 DTx products have been tested in more than 25 randomized controlled trials involving over 7,000 patients. Flagship product deprexis® has demonstrated efficacy comparable to antidepressants across numerous RCTs.
- Therapeutic areas
- OtherPsychiatryNeurology
- Modalities
- Digital therapeuticSoftware as a Medical Device (SaMD)
- Industry
- Digital Health Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
AirbusAOK Health Insurance FundB. Braun Melsungen AGFerring PharmaceuticalsEli LillyJohnson & JohnsonLundbeckMerck KGaAMerz PharmaOrexo ABPfizer Inc.Servier Laboratories
Beyond the preview
Go deeper on GAIA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAIA.